Clinical trials
Leukemia, Myeloid, Acute trials in Japan
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
76 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2006 | 1 |
| 2007 | 1 |
| 2009 | 1 |
| 2010 | 1 |
| 2011 | 3 |
| 2012 | 3 |
| 2013 | 3 |
| 2014 | 4 |
| 2015 | 5 |
| 2016 | 7 |
| 2017 | 9 |
| 2018 | 8 |
| 2019 | 3 |
| 2020 | 7 |
| 2021 | 5 |
| 2022 | 4 |
| 2023 | 2 |
| 2024 | 3 |
| 2025 | 2 |
| 2026 | 3 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 43 |
| Terminated | 15 |
| Active, not recruiting | 8 |
| Recruiting | 8 |
| Approved for marketing | 1 |
| Enrolling by invitation | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| AbbVie | 12 |
| Novartis Pharmaceuticals | 8 |
| Astellas Pharma Global Development, Inc. | 6 |
| Otsuka Pharmaceutical Co., Ltd. | 5 |
| Daiichi Sankyo Co., Ltd. | 4 |
| Amgen | 3 |
| Astex Pharmaceuticals, Inc. | 3 |
| AstraZeneca | 3 |
| Pfizer | 3 |
| Astellas Pharma Inc | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Leukemia, Myeloid, Acute | 76 |
| Myelodysplastic Syndromes | 16 |
| Neoplasms | 11 |
| Lymphoma, Non-Hodgkin | 8 |
| Multiple Myeloma | 8 |
| Hematologic Neoplasms | 6 |
| Leukemia | 6 |
| Leukemia, Myelomonocytic, Chronic | 5 |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 5 |
| Recurrence | 5 |
Trials
Showing 76 to 76 of 76. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.